Literature DB >> 26034202

Tumor necrosis factor receptor-associated factor 3 is a positive regulator of pathological cardiac hypertrophy.

Xi Jiang1, Ke-Qiong Deng1, Yuxuan Luo1, Ding-Sheng Jiang1, Lu Gao1, Xiao-Fei Zhang1, Peng Zhang1, Guang-Nian Zhao1, Xueyong Zhu1, Hongliang Li2.   

Abstract

Cardiac hypertrophy, a common early symptom of heart failure, is regulated by numerous signaling pathways. Here, we identified tumor necrosis factor receptor-associated factor 3 (TRAF3), an adaptor protein in tumor necrosis factor-related signaling cascades, as a key regulator of cardiac hypertrophy in response to pressure overload. TRAF3 expression was upregulated in hypertrophied mice hearts and failing human hearts. Four weeks after aortic banding, cardiac-specific conditional TRAF3-knockout mice exhibited significantly reduced cardiac hypertrophy, fibrosis, and dysfunction. Conversely, transgenic mice overexpressing TRAF3 in the heart developed exaggerated cardiac hypertrophy in response to pressure overload. TRAF3 also promoted an angiotensin II- or phenylephrine-induced hypertrophic response in isolated cardiomyocytes. Mechanistically, TRAF3 directly bound to TANK-binding kinase 1 (TBK1), causing increased TBK1 phosphorylation in response to hypertrophic stimuli. This interaction between TRAF3 and TBK1 further activated AKT signaling, which ultimately promoted the development of cardiac hypertrophy. Our findings not only reveal a key role of TRAF3 in regulating the hypertrophic response but also uncover TRAF3-TBK1-AKT as a novel signaling pathway in the development of cardiac hypertrophy and heart failure. This pathway may represent a potential therapeutic target for this pathological process.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  MAP kinase signaling system; TNF receptor-associated factor 3; cardiomegaly

Mesh:

Substances:

Year:  2015        PMID: 26034202     DOI: 10.1161/HYPERTENSIONAHA.115.05469

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

1.  Cdon deficiency causes cardiac remodeling through hyperactivation of WNT/β-catenin signaling.

Authors:  Myong-Ho Jeong; Hyun-Ji Kim; Jung-Hoon Pyun; Kyu-Sil Choi; Dong I Lee; Soroosh Solhjoo; Brian O'Rourke; Gordon F Tomaselli; Dong Seop Jeong; Hana Cho; Jong-Sun Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-02       Impact factor: 11.205

2.  An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury.

Authors:  Xiao-Jing Zhang; Xu Cheng; Zhen-Zhen Yan; Jing Fang; Xiaozhan Wang; Weijun Wang; Zhen-Yu Liu; Li-Jun Shen; Peng Zhang; Pi-Xiao Wang; Rufang Liao; Yan-Xiao Ji; Jun-Yong Wang; Song Tian; Xue-Yong Zhu; Yan Zhang; Rui-Feng Tian; Lin Wang; Xin-Liang Ma; Zan Huang; Zhi-Gang She; Hongliang Li
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

3.  Mesenchymal Stem Cell-Derived Exosome-Loaded microRNA-129-5p Inhibits TRAF3 Expression to Alleviate Apoptosis and Oxidative Stress in Heart Failure.

Authors:  Fang Yan; Wei Cui; Ziying Chen
Journal:  Cardiovasc Toxicol       Date:  2022-05-12       Impact factor: 3.231

4.  The Chx10-Traf3 Knockout Mouse as a Viable Model to Study Neuronal Immune Regulation.

Authors:  Jami M Gurley; Grzegorz B Gmyrek; Elizabeth A Hargis; Gail A Bishop; Daniel J J Carr; Michael H Elliott
Journal:  Cells       Date:  2021-08-12       Impact factor: 7.666

Review 5.  Recent advances of adapter proteins in the regulation of heart diseases.

Authors:  Li Tao; Linna Jia; Yuntian Li; Chengyun Song; Zheng Chen
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

6.  TRAF molecules in inflammation and inflammatory diseases.

Authors:  Almin I Lalani; Sining Zhu; Samantha Gokhale; Juan Jin; Ping Xie
Journal:  Curr Pharmacol Rep       Date:  2017-12-20

Review 7.  Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Authors:  Hyun Ho Park
Journal:  Arch Pharm Res       Date:  2021-05-10       Impact factor: 4.946

8.  Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy.

Authors:  Ke-Qiong Deng; Aibing Wang; Yan-Xiao Ji; Xiao-Jing Zhang; Jing Fang; Yan Zhang; Peng Zhang; Xi Jiang; Lu Gao; Xue-Yong Zhu; Yichao Zhao; Lingchen Gao; Qinglin Yang; Xue-Hai Zhu; Xiang Wei; Jun Pu; Hongliang Li
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

9.  The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.

Authors:  Yan-Xiao Ji; Peng Zhang; Xiao-Jing Zhang; Yi-Chao Zhao; Ke-Qiong Deng; Xi Jiang; Pi-Xiao Wang; Zan Huang; Hongliang Li
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

10.  Tripartite motif 32 prevents pathological cardiac hypertrophy.

Authors:  Lijuan Chen; Jia Huang; Yanxiao Ji; Xiaojing Zhang; Pixiao Wang; Keqiong Deng; Xi Jiang; Genshan Ma; Hongliang Li
Journal:  Clin Sci (Lond)       Date:  2016-02-16       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.